2023 World Conference on Lung Cancer (Posters)-EP12.01. Clinical Features, Outcomes, and Biology of EGFR exon 20 Insertions in a Cohort of Hispanic Patients with Non-small Cell Lung Cancer

EP12.01. Clinical Features, Outcomes, and Biology of EGFR exon 20 Insertions in a Cohort of Hispanic Patients with Non-small Cell Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

This study evaluated the clinical features, outcomes, and biology of EGFR exon 20 insertions in a cohort of Hispanic patients with non-small cell lung cancer (NSCLC). The study included 93 patients with a mean age of 59.1 years, the majority of whom were women and had adenocarcinoma histology. The most common EGFR exon 20 insertion subtypes were H773insH, V769_D770insASV, H773_V774insPH, and A763_Y764insFQEA. Different treatment regimens were used, including chemotherapy (52.7%), 1st-generation tyrosine-kinase inhibitors (21.5%), and others. The patients treated with CTBevacizumab and 1st-generation TKIs had improved progression-free survival (PFS), while those treated with osimertinib and afatinib did not show significant improvements. Osimertinib, CTBevacizumab, and 1st-generation TKIs were associated with longer median overall survival (mOS) compared to chemotherapy alone. Six patients treated with anti-EGFR exon20ins agents had longer mOS compared to those who did not receive this treatment, although the difference was not statistically significant. Overall, the study suggests that osimertinib, CTBevacizumab, and 1st-generation TKIs may provide some benefit for NSCLC patients with EGFR exon 20 insertion mutations. Additionally, it highlights the potential of anti-EGFR exon20ins agents as a priority need for improving overall survival in this population. The study was conducted retrospectively across multiple cancer centers in various countries, including Peru, Colombia, Brazil, Ecuador, Argentina, Venezuela, Mexico, the United States, Spain, Panama, Costa Rica, and Nicaragua. Hazard ratios were used to evaluate progression-free survival and overall survival.

Asset Subtitle

Andres Cardona

Meta Tag

Speaker Andres Cardona

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

EGFR exon 20 insertions

Hispanic patients

non-small cell lung cancer

adenocarcinoma histology

chemotherapy

tyrosine-kinase inhibitors

CTBevacizumab

osimertinib

afatinib

anti-EGFR exon20ins agents